A Trial to Compare Efficacy and Safety of Follitropin Delta Versus Placebo (Inactive Treatment) in the Treatment of Men With Idiopathic Infertility (Unexplained Reduction of Semen Quality) (ADAM)
The primary purpose of this trial is to investigate whether men with idiopathic infertility (unexplained reduction of semen quality), after being treated with a daily dose of 12 µg recombinant follicle stimulating hormone (rFSH) for 6 months, can improve the chance of spontaneous pregnancy observed in their female partners in comparison to placebo (inactive treatment). For more information, please visit the trial's website www.adamclinicaltrial.com (only applicable in the US).
Conditions:
Male Idiopathic Infertility
Study Start (Actual) 2022-08-16
Primary Completion (Estimated) 2026-07-15
Study Completion (Estimated) 2026-07-15
Enrollment (Estimated) 400
Study Type INTERVENTIONAL
Phase PHASE2
Locations:
📍 Tempe, Arizona, United States
📍 San Jose, California, United States
📍 Centennial, Colorado, United States
📍 Newark, Delaware, United States
📍 Chicago, Illinois, United States
📍 Chicago, Illinois, United States
📍 Kansas City, Kansas, United States
📍 New York, New York, United States
📍 Raleigh, North Carolina, United States
📍 Oklahoma City, Oklahoma, United States
📍 Bedford, Texas, United States
📍 Webster, Texas, United States
📍 Salt Lake City, Utah, United States
📍 Seattle, Washington, United States
📍 Brussels, Belgium
📍 Brussel, Belgium
📍 Copenhagen, Denmark
📍 Halle, Germany
📍 Muenster, Germany
📍 Modena, Italy
📍 Rome, Italy
📍 Valencia, Spain
📍 Malmö, Sweden
📍 Stockholm, Sweden

Eligibility Criteria

Description

    Inclusion Criteria:

    • * History of infertility for 12-60 months with current partner at randomization.
    • * Men between the ages of 18 and 50 years.
    • * Total sperm count 5-39 million at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomization.
    • * Total motile sperm count of 5-16 million at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomization.
    • * Semen volume ≥1.4 mL at screening; confirmed by two consecutive samples taken ≥2 weeks apart before randomization.
    • * Serum follicle-stimulating hormone (FSH) levels of 1.5-8.0 IU/L (measured at central laboratory) at screening. (Approved in US: FSH levels of 2-12.0 IU/L (measured at central laboratory) at screening)
    • * Serum luteinising hormone (LH) levels of 1.2-7.5 IU/L (measured at central laboratory) at screening.
    • * Serum total testosterone levels of ≥300 ng/dL (equals ≥10.4 nmol/L; measured at central laboratory) at screening.
    • * Agree to have regular intercourse with current female partner with the intent of spontaneous conception within 9 months from randomization.
    • * Agree to provide information on female partner's positive urine pregnancy test(s) and documentation of ultrasound(s), delivery, and neonatal/infant health.
    • Current partner fulfilling the criteria below:
    • * Pre-menopausal woman between the ages of 18 and 35 years. (Approved in US: Pre-menopausal woman between the ages of 18 and 38 years.)
    • * Regular menstrual cycles of 21-35 days.
    • * No history or current condition of pelvic inflammatory disease, endometriosis stage II-IV by definite or empirical diagnosis, or tubal ligation.
    • * Agree not to obtain infertility treatment outside of this trial for 9 months from randomization of male subject. (Approved in US: However, after 6 months from randomisation, the subject's semen can be used in infertility treatment procedures of his partner.)

    Exclusion Criteria:

    • * Previous FSH treatment not leading to conception. (Approved in US: Previous FSH treatment for ≥4 months not leading to conception.)
    • * Past or current use of finasteride within 3 months prior to screening.
    • * Any history of anatomical disorder of the pituitary gland or testes.
    • * Any structural abnormalities of the vas deferens (unilateral or bilateral) at screening.
    • * Any known, clinically significant, systemic disease in addition to the trial indication that might negatively impact fertility.
    • * Known history or presence of clinical varicocele (subclinical and Grade 1 varicocele are acceptable).
    • * Known history of cryptorchidism, testicular torsion, or orchitis.
    • * Known abnormal karyotype (including Y-chromosome microdeletion).
    • * Current or past treatment of urogenital (kidney, bladder, testicular, or prostate) cancer as well as history of chemo- or radiotherapy that can have impact on testes.
    • * Any known uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary disorders).
    • * Administration of hormonal preparations, agents known to impair testicular function or affect sex hormone secretion, and known or suspected teratogens within 3 months prior to screening. Administration of anabolic steroids within 12 months prior to screening.
Ages Eligible for Study: 18 Years to 50 Years (ADULT)
Sexes Eligible for Study: MALE
Accepts Healthy Volunteers: No

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted2022-05-30
  • First Submitted that Met QC Criteria2022-05-30
  • First Posted2022-06-03

Study Record Updates

  • Last Update Submitted that Met QC Criteria2024-05-29
  • Last Update Posted2024-05-30
  • Last Verified2024-05